DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01232244

Completed

Oxyntomodulin, Mechanisms of Action in Relation to Appetite, Food Intake, Gastric Emptying and Energy Expenditure.

Asset

GLP-1 / incretin class catch-all

Intravenous

Listed sites

1

Recruiting sites

—

Enrollment

15

actual

Study population

Healthy volunteers

Key I/E criterion

•Male

Primary endpoints

•Gastric emptying•Satiety•Hunger

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01232244
Org study IDOXMDissek

Timeline

Milestones

Study first posted2010-11-02estimated
Last update posted2013-12-10estimated
Study start2010-10 (month precision)
Primary completion2012-01actual (month precision)
Study completion2012-01actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexMale
Healthy volunteersAccepted
Sampling methodNon probability sample

Study population text

Healthy young males

Inclusion criteria

•Normal fasting plasma glucose
•Normal glucose tolerance
•Normal haemoglobin levels
•Informed content

Exclusion criteria

•Diabetes
•Pre diabetes (impaired glucose tolerance or impaired fasting glucose)
•1st degree relatives with diabetes
•Obesity (BMI > 30)
•Inflammatory bowels disease
•Bowels surgery
•Nephropathy
•Liver disease
•Medication which cannot be on hold for 24h

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Other clinical outcomes
2
Patient-reported / QoL
1
Safety / tolerability / PK
1

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Satiety

Time frame:4 h

descriptive

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint/low confidence

Oxyntomodulin

Time frame:4 h

concentration, descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint/low confidence

Gastric emptying

Time frame:4 h

descriptive

Primary/protocol endpoint/low confidence

Hunger

Time frame:4 h

descriptive

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

basal energy expenditure

Time frame:2 x 30min

descriptive

Secondary/protocol endpoint/low confidence

GLP-1

Time frame:4 h

descriptive

Secondary/protocol endpoint/low confidence

Glucagon

Time frame:4 h

descriptive

Secondary/protocol endpoint/low confidence

GIP

Time frame:4 h

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.